MOL-75-CD1: Structure-Guided Candidate Prioritization, Conditional Dose–Release Modeling, SBECD Excipient Pharmacokinetics, and Amyloid-β/Tau Response Analysis for an Alzheimer's Disease Therapeutic Strategy
Authors/Creators
Description
Background: Alzheimer's disease (AD) involves interacting amyloid-β (Aβ), tau, oxidative stress and proteostasis mechanisms; development of a CNS-directed small-molecule candidate requires joint assessment of chemical properties, delivery, exposure and pharmacodynamic response [1–4]. Objective: To characterize MOL-75 (SMILES: COc1cc(CCNC(=O)CCCc2cccnc2)ccc1O), investigate a low-exposure sulfobutylether-β-cyclodextrin (SBECD) formulation concept named MOL-75-CD1, and quantify model-defined design windows against experimental literature. Methods: A 201-structure ADMETlab 3.0 export was interrogated using cheminformatics and multi-criterion screening. The MOL-75 ADMET profile was carried forward into deterministic mass-balance dose–release calculations, a four-half-life SBECD elimination study, twelve excipient-mass illustrations, thirty-six delivery combinations, 192 amyloid/tau/proteostasis ordinary differential equation (ODE) evaluations and conditional CYP inhibition screening. Published primary neuronal experiments, a randomized NAC trial, a human SBECD clinical pharmacokinetic study and a mouse nanoparticle experiment were evaluated separately from model-generated outcomes. Results: Sixteen near-neighbor structures passed the similarity screen and six passed an eight-endpoint model-score filter; MOL-75 remained the prespecified lead. At D=1/5.25, assumed brain transfer b=0.07, brain release gB=0.90, off-target immediate release gS=0.05 and delayed release q=0.005, the modeled delivery window was D=0.15873–0.19640. The chosen D=0.19048 produced normalized brain release 0.012 and off-target release 0.009699. SBECD half-life of 1.8 h, grounded in human data, yielded 0.0097% modeled residual carrier at 24 h, whereas 10.8 h yielded 21.43%. Conditional pharmacodynamic response at 90 days with an assumed MOL-75 Emax=0.30 and NAC stress effect=0.10 was Aβ -14.05%, tau -11.14% and proteostasis stress -20.42%; zero assumed MOL-75 activity yielded no modeled Aβ/tau reduction. Conclusions: MOL-75-CD1 represents a computationally specified therapeutic candidate strategy and a reproducible prioritization framework. The output-defined dose window is a design criterion, not an observed therapeutic index, and SBECD alone does not establish brain-targeted gated delivery.